Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
Associated Neurologists of Southern Connecticut, PC
mi
from
Fairfield, CT
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
Associated Neurologists of Southern Connecticut, PC
mi
from
Fairfield, CT
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
The University of California, San Diego
mi
from
La Jolla, CA
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
The University of California, San Diego
mi
from
La Jolla, CA
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
Stanford University
mi
from
Stanford, CA
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
Yale University, Yale Cancer Center
mi
from
New Haven, CT
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
Yale University, Yale Cancer Center
mi
from
New Haven, CT
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
University of Miami
mi
from
Miami, FL
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
Moffitt Cancer Center
mi
from
Tampa, FL
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
University of Kansas Medical Center
mi
from
Kansas City, KA
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
Abbott Northwestern Hospital / Allina Health
mi
from
Minneapolis, MN
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
Abbott Northwestern Hospital / Allina Health
mi
from
Minneapolis, MN
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
Overlook Medical Center
mi
from
Summit, NJ
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
Overlook Medical Center
mi
from
Summit, NJ
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
NYU Langone Medical Center
mi
from
New York, NY
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
NYU Langone Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
Columbia University
mi
from
New York, NY
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
Sanford Research
mi
from
Sioux Falls, SD
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
Sanford Research
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Medical Center
mi
from
Nashville, TN
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin
mi
from
Madison, WI
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
Ohio State University
mi
from
Columbus, OH
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University
mi
from
Philadelphia, PA
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
University of Alberta
mi
from
Edmonton,
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
University of Alberta
mi
from
Edmonton,
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
Colorado Neurological Institute
mi
from
Englewood, CO
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
Colorado Neurological Institute
mi
from
Englewood, CO
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
Stony Brook University Hospital
mi
from
Stony Brook, NY
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
Stony Brook University Hospital
mi
from
Stony Brook, NY
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
Cincinnati's Children's Hospital Medical Center
mi
from
Cincinnati, OH
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
Cincinnati's Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
INOVA Dwight and Martha Schar Cancer Institute
mi
from
Fairfax, VA
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
INOVA Dwight and Martha Schar Cancer Institute
mi
from
Fairfax, VA
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
St. Joseph Hospital
mi
from
Orange, CA
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
St. Joseph Hospital
mi
from
Orange, CA
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
University of Colorado Cancer Center
mi
from
Aurora, CO
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
University of Colorado Cancer Center
mi
from
Aurora, CO
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
Houston Methodist Hospital Outpatient Center
mi
from
Houston, TX
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
Houston Methodist Hospital Outpatient Center
mi
from
Houston, TX
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
Sentara Neurosurgery Specialists
mi
from
Norfolk, VA
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
Sentara Neurosurgery Specialists
mi
from
Norfolk, VA
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
North Shore University Hospital
mi
from
Lake Success, NY
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
North Shore University Hospital
mi
from
Lake Success, NY
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
Barrow Neurological Institute at Dignity Health St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
Barrow Neurological Institute at Dignity Health St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
Washington University in St. Louis
mi
from
Saint Louis, MO
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
Washington University in St. Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
Univ of Minnesota
mi
from
Minneapolis, MN
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
HCA Midwest / Sarah Cannon
mi
from
Kansas City, MO
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
HCA Midwest / Sarah Cannon
mi
from
Kansas City, MO
Click here to add this to my saved trials
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated:  12/31/1969
University Hospitals of Cleveland Medical Center
mi
from
Cleveland, OH
The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Status: Enrolling
Updated: 12/31/1969
University Hospitals of Cleveland Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
A Phase 2, Multicenter Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
Status: Enrolling
Updated:  12/31/1969
Beverly Hills Cancer Center
mi
from
Beverly Hills, CA
Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
A Phase 2, Multicenter Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
Status: Enrolling
Updated: 12/31/1969
Beverly Hills Cancer Center
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
A Phase 2, Multicenter Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
Status: Enrolling
Updated:  12/31/1969
University of Colorado Cancer Center
mi
from
Aurora, CO
Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
A Phase 2, Multicenter Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
Status: Enrolling
Updated: 12/31/1969
University of Colorado Cancer Center
mi
from
Aurora, CO
Click here to add this to my saved trials
Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
A Phase 2, Multicenter Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
Status: Enrolling
Updated:  12/31/1969
Georgetown University Medical Center
mi
from
Washington,
Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
A Phase 2, Multicenter Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
Status: Enrolling
Updated: 12/31/1969
Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
A Phase 2, Multicenter Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
Status: Enrolling
Updated:  12/31/1969
John Wayne Cancer Institute
mi
from
Santa Monica, CA
Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
A Phase 2, Multicenter Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
Status: Enrolling
Updated: 12/31/1969
John Wayne Cancer Institute
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
A Phase 2, Multicenter Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
Status: Enrolling
Updated:  12/31/1969
Sarah Cannon Research Institute
mi
from
Nashville, TN
Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
A Phase 2, Multicenter Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
Status: Enrolling
Updated: 12/31/1969
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
A Phase 2, Multicenter Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
Status: Enrolling
Updated:  12/31/1969
UT MD Anderson Cancer Center
mi
from
Houston, TX
Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
A Phase 2, Multicenter Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
Status: Enrolling
Updated: 12/31/1969
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
A Phase 2, Multicenter Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
Status: Enrolling
Updated:  12/31/1969
USC Norris Oncology/Hematology-Newport Beach
mi
from
Newport Beach, CA
Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
A Phase 2, Multicenter Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases
Status: Enrolling
Updated: 12/31/1969
USC Norris Oncology/Hematology-Newport Beach
mi
from
Newport Beach, CA
Click here to add this to my saved trials
A Novel Health Information Technology System (BMT Roadmap) for Pediatric BMT Patients and Caregivers
A Novel Health Information Technology System (BMT Roadmap) for Pediatric BMT Patients and Caregivers
Status: Enrolling
Updated:  12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
A Novel Health Information Technology System (BMT Roadmap) for Pediatric BMT Patients and Caregivers
A Novel Health Information Technology System (BMT Roadmap) for Pediatric BMT Patients and Caregivers
Status: Enrolling
Updated: 12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Intraoperative Imaging of Pituitary Adenomas by OTL
A Phase 1, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection for Intraoperative Imaging of Folate Receptor-alpha Positive Pituitary Adenoma
Status: Enrolling
Updated:  12/31/1969
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Intraoperative Imaging of Pituitary Adenomas by OTL
A Phase 1, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection for Intraoperative Imaging of Folate Receptor-alpha Positive Pituitary Adenoma
Status: Enrolling
Updated: 12/31/1969
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma
Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma
Status: Enrolling
Updated:  12/31/1969
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma
Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma
Status: Enrolling
Updated: 12/31/1969
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors
A Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University-Sidney Kimmel Cancer Center
mi
from
Baltimore, MD
Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors
A Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University-Sidney Kimmel Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors
A Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors
A Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors
A Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors
A Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors
A Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors
Status: Enrolling
Updated:  12/31/1969
NCI - Center for Cancer Research
mi
from
Bethesda, MD
Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors
A Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors
Status: Enrolling
Updated: 12/31/1969
NCI - Center for Cancer Research
mi
from
Bethesda, MD
Click here to add this to my saved trials